8-K: Day One Biopharma Reprices Executive Stock Options

Day One Biopharmaceuticals' Board approved an option repricing for certain directors and employees, including named executive officers, to retain and motivate key talent.

Summary

• The Board approved an option repricing for outstanding stock options held by certain current directors and employees, including named executive officers.
• Options with an exercise price per share of $8.00 or greater are eligible for repricing.
• The new exercise price will be equal to the closing price of the Company's common stock on the Effective Date.
• The repricing aims to retain and motivate key contributors without incurring significant additional equity grants or cash expenditures.
• Eligible participants must remain in service through a Retention Period (earlier of one-year anniversary of Effective Date or a Corporate Transaction) to exercise at the new price.
• Named executive officers affected include Jeremy Bender (President & CEO) with 2,676,134 repriced options, Charles York (COO & CFO) with 1,088,667 repriced options, and Adam Dubow (General Counsel, CCO & Secretary) with 270,000 repriced options, all with original exercise prices ranging from $11.87 to $23.41.
• Adam Dubow also received an additional stock option grant of 309,000 shares on the Effective Date, with an exercise price equal to the new repricing price, to align his incentives.

Sentiment

Score: 4

Explanation: While management frames the repricing as a necessary tool for retention and motivation, option repricings are generally viewed negatively by shareholders. They can dilute existing shareholder value and reward management for past stock underperformance. The inclusion of a retention period and the stated goal of avoiding *additional* dilution are minor positives, but the overall sentiment from a shareholder perspective is likely cautious to negative.

Positives

• Aims to retain and motivate key contributors, including executive officers, which is crucial for company stability and future performance.
• Structured to avoid significant additional equity grants, thereby mitigating further dilution from new awards.
• Avoids significant additional cash expenditures for compensation, preserving cash reserves.
• Includes a Retention Period requirement, ensuring continued service from eligible participants to benefit from the repricing.

Negatives

• Option repricing can be viewed negatively by shareholders as it effectively rewards management for a decline in stock price, potentially signaling a lack of accountability.
• While avoiding *additional* dilution from new grants, the repricing itself can be perceived as a transfer of value from existing shareholders to option holders.
• May signal management's lack of confidence in the company's near-term stock price recovery if repriced options are deemed necessary for motivation.

Risks

• Potential for shareholder dissatisfaction and negative market perception due to the repricing event.
• Risk of key talent departure if the repricing is not perceived as sufficiently motivating or if the stock price continues to underperform.
• Potential for increased future compensation expense if the stock price recovers significantly, leading to more in-the-money options.

Future Outlook

The repricing is intended to ensure the retention and motivation of key personnel, suggesting a strategic focus on maintaining critical talent for future company performance and development. The vesting schedule for the new stock option granted to Mr. Dubow, set for the one-year anniversary of the Effective Date, indicates a short-to-medium term incentive horizon for executive alignment.

Management Comments

• The Board and Compensation Committee approved the Repricing in order to retain and motivate key contributors of the Company without incurring dilution resulting from significant additional equity grants to the Company's employees or significant additional cash expenditures resulting from cash compensation.

Industry Context

Option repricing is a contentious but occasionally employed strategy in the biotechnology and pharmaceutical sectors, particularly for companies experiencing significant stock price declines. It is often used to re-incentivize and retain critical scientific and executive talent whose existing options are underwater, preventing their departure to competitors in a highly competitive industry where human capital is paramount.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential negative impact due to perceived dilution of existing equity and the optics of rewarding management after a period of stock price decline, which could lead to decreased investor confidence.
• Employees (Eligible Participants): Positive impact through re-incentivization and increased motivation, particularly for those whose existing options were underwater, enhancing retention.
• Management: Directly benefits from repriced options, which are intended to enhance retention and motivation, aligning their incentives more closely with a potential future stock price recovery.

Next Steps

• The Effective Date of the repricing will occur on the second full business day following the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.
• Eligible participants must remain in service through the Retention Period (one year from the Effective Date or until a Corporate Transaction) to exercise their repriced options at the new, lower price.
• Adam Dubow's new stock option grant of 309,000 shares will vest and become exercisable on the one-year anniversary of the Effective Date.

Key Dates

Recommendation

While option repricing is generally a negative signal for shareholders, the company has explicitly stated its goal is to retain key talent without incurring significant additional dilution or cash outlay, and has included a retention period. This suggests a strategic move to stabilize the executive team during a challenging period. However, this action does not fundamentally alter the company's underlying business prospects or provide a strong 'buy' signal. Investors should hold and monitor future operational performance and stock price recovery, as the repricing itself doesn't warrant an immediate 'sell' given the stated retention goals, but also doesn't present a compelling reason to increase exposure.

Keywords

Day One Biopharmaceuticals, DAWN, Stock Options, Option Repricing, Executive Compensation, Corporate Governance, Biotechnology, Retention, SEC Filing, 8-K